Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;33(7):1327-31.
doi: 10.1093/carcin/bgs147. Epub 2012 Apr 12.

GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes

Jingyao Dai  1 , Jian Gu, Maosheng Huang, Cathy Eng, E Scott Kopetz, Lee M Ellis, Ernest Hawk, Xifeng Wu
Affiliations

GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes

Jingyao Dai et al. Carcinogenesis. 2012 Jul.

Abstract

Recent genome-wide association studies (GWAS) have identified several common susceptibility loci associated with the risk of colorectal cancer (CRC). However, whether these loci affect clinical outcomes of CRC is not clear. In this study, we genotyped 26 single nucleotide polymorphisms (SNPs) in 10 GWAS-identified CRC susceptibility regions and evaluated their associations with survival and recurrence in 285 stage II and III patients receiving fluorouracil-based adjuvant chemotherapy. Only one SNP, rs10318 (15q13.3), was significantly associated with recurrence for patients with stage II disease. Three SNPs: rs10749971 (11q23.1), rs961253 (20p12.3) and rs355527 (20p12.3) in two regions were significantly associated with recurrence for patients with stage III disease. Five SNPs: rs961253 (20p12.3), rs355527 (20p12.3), rs4464148 (18q21.1), rs6983267 (8q24.21) and rs10505477 (8q24.21) in three regions were significantly associated with survival for patients with stage III disease. Cumulative effects of multiple unfavorable genotypes were observed for recurrence and survival in patients with stage III CRC. Our results suggest that cancer susceptibility loci may also affect the prognosis of CRC patients receiving fluorouracil-based adjuvant chemotherapy.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Kaplan–Meier curves of stage III CRC patients who received 5-FU-based adjuvant chemotherapy stratified by the number of unfavorable genotypes. (A) Overall survival; (B) recurrence-free survival.
See this image and copyright information in PMC

Comment in

References

    1. Siegel R, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011;61:212–236. - PubMed
    1. Andre T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004;350:2343–2351. - PubMed
    1. Andre T, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 2009;27:3109–3116. - PubMed
    1. Pohl A, et al. Pharmacogenomics and -genetics in colorectal cancer. Adv. Drug Deliv. Rev. 2009;61:375–380. - PubMed
    1. Segura C, et al. [Adjuvant treatment of colorectal cancer] Bull Cancer. 2006;93:683–690. - PubMed

Publication types